In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (ABT 1.02%), Johnson & Johnson (JNJ +0.76%), Sanofi (SNY +1.50%), Pfizer (PFE 0.08%), and Merck (MRK 0.98%), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.
